NCT03094845View on ClinicalTrials.gov

Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

September 28, 2016

Primary Completion Date

January 12, 2017

Study Completion Date

January 23, 2017

Conditions

House Dust Mite Allergy

Interventions

BIOLOGICAL

Placebo solution

15 injections over 7 weeks

BIOLOGICAL

hdmASIT+TM

15 injections over 7 weeks

Trial Locations (1)

01307

Universitätsklinikum Carl Gustav Carus, Dresden

Sponsors

Lead Sponsor

ASIT Biotech S.A.

All Listed Sponsors

lead

ASIT Biotech S.A.

INDUSTRY

NCT03094845 - Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients | Biotech Hunter | Biotech Hunter